First talk of the day! #ASCOGI23 ASCO #SanFrancisco

A positive trial in later line #gastroesophageal is always an accomplishment. INTEGRATE IIa meets primary OS endpoint. OncLive.com #GI23

Regorafenib a possible 3rd line in gastro-esophageal adenocarcinoma, interesting results #GI23

Practice-changing research from #GI23: Zolbetuximab + mFOLFOX6 meets primary endpoint in SPOTLIGHT trial, improves PFS, OS in pts w/ CLDN18.2+, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ cancer: fal.cn/3vfjm #ASCODailyNews #gicsm #esocsm

.SWOG Cancer Research Network S1815 results @ #ASCOGI23: Adding nab-paclitaxel to standard gem-cis for patients w advanced #biliary tract cancers did not signif. improve median OS but may benefit patients w locally advanced disease or gallbladder adenocarcinoma. Rachna Shroff, MD, MS, FASCO swog.org/news-events/ne…

🎉 Ecstatic that Ali Alqahtani was awarded an ASCO Conquer Cancer, the ASCO Foundation Merit Award for his oral presentation #GI23 on HER2-high vs. low #gastroesophagealcancer from an analysis of the Caris Life Sciences database ➡️ TWEETORIAL TIME!📢📢Cure GI Cancers Georgetown Lombardi Georgetown Medicine GU Medical Center

Regorafenib an effective treatment in gastro-esophageal refractory disease. Interesting trial ongoing with regorafenib plus nivolumab in the same setting #GI23

🏅Positive trial in Gastric cancer! #ASCOGI23

NAPOLI3. NALIRIFOX new first line standard of care in mPDAC patients. ✅OS ✅PFS ✅ORR 42 vs 36% - Different toxicities profile #ASCOGI23

NAPOLI 3. There's no head to head trial but is really interesting to put this two trials together, specially in countries where nal-iri is not available #ASCOGI23

⛔Negative results for the SWOG-1815 trial. Gem/Cis/NabPaclitaxel vs. Gem/Cis in BTC. -No differences in OS, PFS or ORR. -More toxicity, even 7 grade 5 events -Slight benefit in gallbladder cancer #ASCOGI23

🔥Atezolizumab with or without Beva in combination with GemCis in #biliarytractcancer @ ASCO-GI 2023 ✅ IMbrave-151, 162 pts 👉mOS n.vs 11.4 👉mPFS 8.4 vs 7.9 mo 👉ORR 25 vs 24% 👉Modest benefit with Bev, but OS not yet mature 🧐KEYNOTE-966 awaited ESMO - Eur. Oncology EASL Education ENS-CCA

A 1 año de tu partida. Sigue siendo un tabú. #SaludMental

Para reflexionar

Si van a repostear el vídeo de Sascha porfa póngalo en práctica

🔥Claudin18.who? Examining biomarker overlap and outcomes in claudin 18.2+ g astroesophageal adenocarcinomas ESMO Open doi.org/10.1016/j.esmo… 👏Very nice editorial 👉Gastric cancer on the way to #PrecisionMedicine ESMO - Eur. Oncology OncoAlert

Fresh out of the oven! So PROUD of my brilliant sister! Dr. Carina Nava!!.. Yes! Mine is better than yours 😍😍😎😎

#Astrazeneca is hosting a spotlight event for our late development oncology team. Hear about this amazing group! And discover new job opportunities around the world 🌍🌎🌏 June 21st! Don't miss the opportunity! linkedin.com/posts/mattodon…

💥💥Today!! Don't miss this!